Jessica L Moreno1, Sarah E Wakeman, Matthew S Duprey, Russell J Roberts, Jared S Jacobson, John W Devlin. 1. Department of Quality Management and Patient Safety, Beaumont Health, Southfield, MI (JLM); Substance Use Disorders Initiative, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA (SEW); School of Pharmacy, Northeastern University, Boston, MA (MSD); Department of Pharmacy, Massachusetts General Hospital, Boston, MA (RJR); Department of Health Sciences, Northeastern University, Boston, MA (JSJ); School of Pharmacy, Northeastern University, Boston, MA (JWD).
Abstract
OBJECTIVES: To identify the incidence, characteristics, and predictors for 30 and 90-day readmission among acutely hospitalized patients with opioid use disorder (OUD). METHODS: This retrospective, cohort study evaluated consecutive adults with OUD admitted to an academic medical center over a 5-year period (10/1/11 to 9/30/16). Multivariable logistic regression was used to determine independent predictors for 30 and 90-day readmissions based on pertinent admission, hospital, and discharge variables collected via chart review and found to be different (with a P < 0.10) on univariate analysis. RESULTS: Among the 470 adults (mean age 43.1 ± 12.8 years, past heroin use 77.9%; admission opioid agonist therapy use [buprenorphine 22.6%; methadone 27.0%]; medical [vs surgical] admission 75.3%, floor [vs ICU] admission 93.0%, in-hospital mortality 0.9%), 85 (18.2%) and 151 (32.1%) were readmitted within 30 and 90 days, respectively. Among the 90-day readmitted patients, median time to first readmission was 26 days. Buprenorphine use (vs no use) at index hospital admission was independently associated with reduced 30-day (odds ratio [OR] 0.47, 95% confidence interval [CI] 0.24-0.93) and 90-day (OR 0.57, 95% CI 0.34-0.96) readmission; prior heroin (vs prescription opioid) use was associated with reduced 90-day readmission (OR 0.59, 95% CI 0.37-0.94) and length of hospital stay was associated with both greater 30-day (OR 1.02, 95% CI 1.01-1.05) and 90-day (OR 1.04, 95% CI 1.01-1.06) readmission rates. CONCLUSIONS: Among patients with OUD taking buprenorphine at the time of hospital admission, 30-day and 90-day hospital readmission was reduced by 53% and 43%, respectively.
OBJECTIVES: To identify the incidence, characteristics, and predictors for 30 and 90-day readmission among acutely hospitalized patients with opioid use disorder (OUD). METHODS: This retrospective, cohort study evaluated consecutive adults with OUD admitted to an academic medical center over a 5-year period (10/1/11 to 9/30/16). Multivariable logistic regression was used to determine independent predictors for 30 and 90-day readmissions based on pertinent admission, hospital, and discharge variables collected via chart review and found to be different (with a P < 0.10) on univariate analysis. RESULTS: Among the 470 adults (mean age 43.1 ± 12.8 years, past heroin use 77.9%; admission opioid agonist therapy use [buprenorphine 22.6%; methadone 27.0%]; medical [vs surgical] admission 75.3%, floor [vs ICU] admission 93.0%, in-hospital mortality 0.9%), 85 (18.2%) and 151 (32.1%) were readmitted within 30 and 90 days, respectively. Among the 90-day readmitted patients, median time to first readmission was 26 days. Buprenorphine use (vs no use) at index hospital admission was independently associated with reduced 30-day (odds ratio [OR] 0.47, 95% confidence interval [CI] 0.24-0.93) and 90-day (OR 0.57, 95% CI 0.34-0.96) readmission; prior heroin (vs prescription opioid) use was associated with reduced 90-day readmission (OR 0.59, 95% CI 0.37-0.94) and length of hospital stay was associated with both greater 30-day (OR 1.02, 95% CI 1.01-1.05) and 90-day (OR 1.04, 95% CI 1.01-1.06) readmission rates. CONCLUSIONS: Among patients with OUD taking buprenorphine at the time of hospital admission, 30-day and 90-day hospital readmission was reduced by 53% and 43%, respectively.
Authors: Kelsey C Priest; Travis I Lovejoy; Honora Englander; Sarah Shull; Dennis McCarty Journal: J Gen Intern Med Date: 2020-04-14 Impact factor: 5.128
Authors: Jessica L Moreno; Matthew S Duprey; Bryan D Hayes; Kirsten Brooks; Sabrina Khalil; Sarah E Wakeman; Russell J Roberts; Jared S Jacobson; John W Devlin Journal: Toxicol Commun Date: 2019-12-09
Authors: R Michael Krausz; Jean N Westenberg; Nickie Mathew; George Budd; James S H Wong; Vivian W L Tsang; Marc Vogel; Conor King; Vijay Seethapathy; Kerry Jang; Fiona Choi Journal: Int J Ment Health Syst Date: 2021-12-20
Authors: Pouya Azar; Jean N Westenberg; Martha J Ignaszewski; James S H Wong; George Isac; Nickie Mathew; R Michael Krausz Journal: Addict Sci Clin Pract Date: 2022-04-05
Authors: Ashish P Thakrar; David Furfaro; Sara Keller; Ryan Graddy; Megan Buresh; Leonard Feldman Journal: J Hosp Med Date: 2021-06 Impact factor: 2.899